bannerHON
img
HONnews
HONnews
img PATIENT / PARTICULIER img PROFESSIONNEL DE SANTE img WEBMESTRE img
img
 
img
HONcode sites
Khresmoi - new !
HONselect
News
Conferences
Images

Themes:
A B C D E F G H I
J K L M N O P Q
R S T U V W X Y Z
Browse archive:
2019: S A J J M A M F J
2018: D N O S

 
  Other news for:
Pancreatic Neoplasms
Drug Therapy
Hereditary Diseases
Genetics
 Resources from HONselect
Genomics Could Improve Treatment of Pancreatic Cancer

By Robert Preidt

THURSDAY, March 14, 2019 (HealthDay News) -- It's one of the toughest cancers to beat. But new research suggests that identifying the genetics of pancreatic cancer in individual patients could boost survival for some.

The five-year survival rate for pancreatic cancer patients is less than 9 percent. One reason this cancer is so deadly is that many patients are diagnosed at a late stage and often with inoperable tumors.

In some cases, existing chemotherapy drugs might be able to shrink pancreatic tumors if the disease is diagnosed early enough.

In this study, University of Pittsburgh researchers analyzed the genomes of nearly 3,600 pancreatic tumor samples from around the world. In 17 percent, genetics suggested the tumor would respond to existing chemotherapy drugs.

The team also found evidence of hereditary genes -- including some in the BRCA family associated with breast cancer -- that can increase an entire family's risk of pancreatic cancer.

"People have been looking for such markers for a long time, and our study shows that it's possible to break pancreatic cancer patients into different treatment buckets," senior author Dr. Nathan Bahary, an associate professor of medicine, said in a university news release.

Lead author Dr. Aatur Singhi, an assistant professor of pathology, noted that every pancreatic cancer is different. Developing a molecular profile of each patient's tumor could help determine the best treatments, he said.

"Rather than blindly giving patients the same chemotherapy, we want to tailor a patient's chemo to their tumor type. A one-size-fits-all approach isn't going to work. Therefore, we would like to make molecular profiling standard of care for patients with pancreatic cancer," Singhi said in the news release.

The study was recently published online in the journal Gastroenterology.

Singhi and colleagues previously developed a test to evaluate common pancreatic cysts and identify which might progress to cancer. These newly discovered biomarkers can be added to the test, which is already in use at several institutions.

More information

The U.S. National Cancer Institute has more on pancreatic cancer.

SOURCE: University of Pittsburgh, news release, March 4, 2019

Copyright © 2019 HealthDay. All rights reserved. URL:http://consumer.healthday.com/Article.asp?AID=743407

Resources from HONselect: HONselect is the HON's medical search engine. It retrieves scientific articles, images, conferences and web sites on the selected subject.
Neoplasms
Pancreatic Neoplasms
Therapeutics
Drug Therapy
Specialty Chemicals and Products
Family
The list of medical terms above are retrieved automatically from the article.

Disclaimer: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources and may not reflect your own country regulations. The Health On the Net Foundation does not endorse opinions, products, or services that may appear in HealthDay articles.


Home img About us img MediaCorner img HON newsletter img Site map img Ethical policies img Contact